top of page

Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial readouts scheduled in DMD and DM1 over the next year

Oct 14, 2025
1 min read

He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data.




Coverage brought to you by


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page